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Renal functionAbstract Background: In a trial to overcome the adverse effects of pneumoperitoneum during
laparoscopic gastric bypass surgery (GBP) on renal function this study investigated the effects of
third generation HES 130/0.4 (6%) on renal function and blood loss during laparoscopic GBP.
Patients and methods: This study was carried out on 83 adult patients of both sexes scheduled for
(GBP) surgery. Patients were randomly classified into Group I (42): received HES 130/0.4 10 ml/kg
to a maximum volume 1000 ml, and Group II (41): received ringer acetate solution 10 ml/kg to a
maximum volume 1000 ml within 30 min pre-operatively.
Mean arterial blood pressure (MABP) and heart rate (HR) were measured before starting of fluid
infusion, and every 15 min till the end of surgery. Blood loss was assessed intraoperatively and
postoperatively.
Intraoperative urine output was observed. Renal functions (blood urea, serum creatinine, and
creatine clearance) were evaluated preoperatively and after 24 h postoperatively.
Results: Intraoperative and postoperative blood loss was comparable in both groups. Changes in
mean arterial blood pressure (MABP), and heart rate (HR) were comparable in both groups except
significant increase in MABP in group I from 30 min till 150 min intraoperatively (p values were
0.04, 0.03, 0.02, 0.04, 0.01, respectively). Creatinine clearance increased significantly at postopera-
tive assessment time in group I, (p= 0.04). There was no significant difference between both groups
regarding serum creatinine and blood urea. Intraoperative urine output significantly increased in
group I, (p= 0.02).
Conclusion: Infusion of HES 130/0.4 has role in prevention of oliguria and provides renal
protection without effect on hemostasis and intraoperative or postoperative blood loss.
 2015 Production and hosting by Elsevier B.V. on behalf of Egyptian Society of Anesthesiologists.
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Nowadays, usage of Laparoscopic gastric bypass surgery for
treatment of obesity is increasing. It has many advantages
for the patients as minimal incision, minimal trauma,
decreased postoperative pain and reduced hospital stay [1].
However, this technique has potential complications as insuf-
flation of carbon dioxide to create a pneumoperitoneum
increases the intra-abdominal pressure which may compromise
the renal function, which depends on different factors as the
level of intra-abdominal pressure, baseline renal function,
intravascular volume status, duration of procedure, and posi-
tion of the patient during procedure [2–4].
This renal impairment is usually transient without sequelae
but it may progress to be of clinical value especially in patients
with impaired renal function or presence of co-morbidities
such as diabetes, elevated intra-abdominal pressure, and
hypertension [5].
HES is a colloid product often used for intravascular vol-
ume expansion in adults, especially in shock state caused by
hemorrhage, burns, surgery, or trauma. It is a heterogeneous
macromolecular agent derived from starch. It has a longer
half-life and maintains hemodynamic stability more efficient
than crystalloids. Its molecular weight is sufficiently low to
allow for adequate metabolism and renal elimination, while
maintaining osmotic activity. This helps to prevent the accu-
mulation of HES in plasma after repeated doses. In recent
studies, the advantage of it in intravascular volume expansion
compared to crystalloids has been marginal [6]. In experimen-
tal studies, colloids demonstrate more rapid resuscitation and
improved tissue perfusion compared to crystalloids [7]. Fur-
thermore, complementary laboratory and clinical research
has demonstrated the negative effects of large volume infusion
of crystalloid that could affect kidney function indirectly [8].
This study was done to evaluate the effect of HES 130/0.4
6% on renal function, urine output, and postoperative bleed-
ing following laparoscopic gastric bypass (GBP) surgery.
1.1. Patients and methods
After approval by our institutional ethical committee, written
consent was obtained from all patients before getting them
involved in the study. The steps of the study, the aims, the
potential benefits and dangers, all were discussed with each
individual patient. 88 enrolled, randomized and allocated into
2 groups and received intervention.
Exclusion criteria included hemoglobin<10 gm/dl or hema-
tocrit <30%, patients with clinically evident limitation of car-
diac or pulmonary function, untreated hypertension, patients
with impaired renal function, patientswith liver disease, patients
with bleeding disorder, and current anticoagulant therapy.
Preoperative examination was done by history taking,
physical examination, and laboratory investigations including
complete blood count, liver function, renal functions, ECG,
chest X-ray, echocardiography, serum electrolytes, PT and
PTT, and Pulmonary function test.
All patients were premedicated with 150 mg ranitidine and
10 mg of metoclopramide one hour before the procedure.
On arrival to the pre-operative preparation room, the
patients were classified into 2 groups: Group I (44): received
HES 130/0.4 10 ml/kg to a maximum volume 1000 mlpreoperatively within 30 min, and Group II (44): received
ringer acetate solution 10 ml/kg to a maximum volume
1000 ml preoperatively within 30 min.
Randomization was performed using a computer random
number generator and the assignment entered in sealed envel-
opes that were opened by a chief nurse who did not participate
in patients’ care after obtaining informed consent.
On arrival to operating room the patients were attached to
monitor displaying the following: ECG, noninvasive bloodpres-
sure, pulse oximetry, end tidal carbon dioxide, and heart rate.
The patients were pre-oxygenated for 3 min before induction.
The anesthesia was induced by fentanyl 2 lg/kg, propofol
2 mg/kg and atracurium 0.5 mg/kg. After manual ventilation
for three minutes endotracheal tube (ETT) was inserted and
confirmed by clinical observation of chest wall movement, aus-
cultation of chest and presence of square wave of capnogram.
Then, the patients were connected to mechanical ventilation.
The respiratory rate and tidal volume were adjusted to main-
tain an ETCO2 between 32 and 35 mmHg.
After securing the ETT, central venous catheter was
inserted through right internal jugular vein for fluids, drugs
infusion and measure the central venous pressure, urinary
catheter was placed for monitoring of urine output and arterial
line was inserted for blood sampling and blood gas.
Anesthesia was maintained by 100% oxygen and isoflurane
1–1.5%. Top up doses of atracurium and fentanyl were given
when needed and the concentration of anesthesia was adjusted
to maintain the BP and HR within 20% from baseline.
1.2. Fluid therapy
On arrival to the pre-operative preparation room, Group I
received HES 130/0.4 10 ml/kg to a maximum volume of
1000 ml, and Group II received ringer acetate solution
10 ml/kg to a maximum volume of 1000 ml.
The subsequent fluid loss intraoperatively was replaced by
ringer solution in a volume 1:1. Blood loss will be replaced
by ringer solution in a volume 3:1 up to loss of 500 ml of blood
and the subsequent blood loss was replaced by blood.
After completion of surgery, inhalational anesthesia was
stopped and muscle relaxant was reversed with atropine and
neostigmine and the patient allowed to breathe spontaneously.
The ETT was removed when the patients fulfilled the crite-
ria of extubation (spontaneous eye opening, purposeful move-
ment, intact reflex). After extubation the patients were
transferred to postanesthesia care unit.
1.3. Measurements
Mean arterial blood pressure (MABP) and heart rate (HR)
were measured before starting of fluid infusion as baseline,
and every 15 min till the end of surgery. Blood loss was
assessed intraoperatively and postoperatively. Intraoperative
urine output was observed. Renal functions (blood urea, serum
creatinine, and creatine clearance) were evaluated preopera-
tively and after 24 h postoperatively.
1.4. Statistical analysis
Sample size calculation was based on the assumption that cre-
atinine clearance is the primary endpoint and 40 patients were
Table 2 Hemodynamic data including mean arterial blood
pressure and heart rate in both groups; data are presented as
mean ± standard deviation.
Hemodynamic data Group I Group II P value
MABP (mmHg)
T0 95 ± 5.7 96 ± 5.6 0.3
T1 90 ± 7.8 80 ± 8.7 0.04*
T2 92 ± 6.7 82 ± 6.8 0.03*
T3 94 ± 7.6 84 ± 7.8 0.02*
T4 92 ± 5.8 80 ± 6.8 0.04*
T5 90 ± 4.9 85.3 ± 6.5 0.01*
T6 87 ± 6.7 86.4 ± 4.3 0. 5
T7 86.3 ± 5.5 86.3 ± 5.8 0.7
HR beat/minute
T0 79 ± 6.5 82 ± 8.6 0.3
T1 86 ± 6.8 90 ± 4.6 0.2
T2 84 ± 5.6 85 ± 6.5 0.6
T3 83 ± 4.7 81 ± 5.8 0.4
T4 86 ± 5.8 88 ± 4.8 0.5
T5 84 ± 4.7 85 ± 4.5 0.5
T6 79 ± 5.4 80 ± 6.8 0.6
T7 81 ± 4.5 82 ± 7.5 0.4
T0 = Base line, T1 = 30 min after induction, T2 = 60 min after
induction, T3 = 90 min after induction, T4 = 120 min after
induction, T5 = 150 min after induction, T6 = 180 min after
induction, T7 = 210 min after induction.
* p value <0.05 (significant difference between both groups).
Table 3 Renal functions including creatinine clearance, serum
creatinine, blood urea and urine output; data are presented as
mean ± standard deviation.
Group I
N= 42
Group II
N= 41
P
value
Creatinine clearance
preoperatively (mL/min)
115 ± 27.6 118 ± 28.7 0.4
Creatinine clearance
postoperatively (mL/min)
140 ± 15.7 100 ± 6.7 0.04
Serum creatinine
preoperatively (mg/dL)
0.7 ± 0.04 0.8 ± 0.06 0.3
Serum creatinine
postoperatively (mg/dL)
0.8 ± 0.07 1.2 ± 0.1 0.5
Blood urea preoperatively 20.8 ± 5.8 22.6 ± 4.3 0.5
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between groups with a 5% (two-sided) type I error. For possi-
bility of dropout of some patients 10% was added to each
group so 44 patients were included in each group. The statisti-
cal analysis was done using SPSS Version 20 for Macintosh.
Demographic, hemodynamic and laboratory data were com-
pared with the t-test, Mann–Whitney U-test or v2-test as
appropriate. The level of statistical significance was set to
allow an alpha error of 5% (value of 0.05).
2. Results
83 patients completed the study protocol: 42 patients in group
I and 41 patients in group II, and 5 patients were excluded
because of changing the procedure plan to open surgery
because of either intraoperative bleeding or extensive adhe-
sion. There were no significant differences between patients
in each group as regards age, sex, body mass index, pneu-
moperitoneum pressure and pneumoperitoneum duration
(Table 1).
Intraoperative and postoperative blood loss was compara-
ble in both groups, p value >0.05, Table 1.
MABP was significantly higher in Group I than Group II at
30, 60, 90, 120 and 150 min (p values were 0.04, 0.03, 0.02,
0.04, 0.01, respectively), Table 2.
Table 3, summarizes the changes in renal parameters and
showed that, at baseline, variables were similar and within
the normal range in both groups. The comparison shows that
creatinine clearance was significantly higher in group I com-
pared with group II, p value 0.04. There was no significant dif-
ference between both groups regarding serum creatinine and
blood urea. Intraoperative urine output was significantly
higher in group I compared with group II p value 0.02.
3. Discussion
Laparoscopic bariatric surgery, particularly laparoscopic
GBP, is a complex operation often associated with a longer
operative time than other commonly performed laparoscopic
procedures. A longer operative time during laparoscopic
GBP translates to longer exposure of the host to the adverse
physiological effects of pneumoperitoneum. Therefore, anes-
thetist giving anesthesia for laparoscopy in morbidly obeseTable 1 Patients characteristics, pneumoperitoneum pressure
and duration; data are presented as mean ± SD or numbers.
Group I
N= 42
Group II
N= 41
P
Age 32.5 ± 11.5 30.4 ± 10.6 0.8
Sex male/female 18/24 17/24 0.4
Body Mass Index (BMI) 53.6 ± 5.9 52.4 ± 7.8 0.6
Pneumoperitoneum pressure
(mmHg)
13.6 ± 0.5 13.4 ± 0.6 0.4
Pneumoperitoneum duration
(min)
180.7 ± 15.7 175.5 ± 20.8 0.7
Intra-operative blood loss
(ml)
150.8 ± 20.8 170.6 ± 18.7 0.6
Post-operative blood loss
(ml)
50.7 ± 15.5 55.7 ± 14.7 0.5
(mg/dL)
Blood urea postoperatively
(mg/dL)
30 ± 7.8 42 ± 6.9 0.06
Intra-operative urine output (l) 1.5 ± 0.04 0.5 ± 0.01 0.02patients should understand the basic physiologic changes
occurring during pneumoperitoneum, recognize the clinical
changes, and make appropriate intraoperative adjustments to
minimize the adverse changes. One of the measures to mini-
mize the effects of increased intraabdominal pressure on renal
and cardiac function is optimization of intravascular volume.
The reduction in intraoperative urine output has been well
documented during laparoscopic operations [9,10] and the
degree of intraoperative oliguria is dependent on the level of
increased intraabdominal pressure; higher intraabdominal pres-
sures resulted in a greater degree of oliguria [10]. Intraoperative
urine output in morbidly obese subjects decreased immediately
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and remained lower than during open GBP [11].
The reduction in intraoperative urine output during laparo-
scopic operations could be explained by: Pneumoperitoneum
has a direct pressure effect on the renal cortical blood flow
[12] and renal vasculature, resulting in reduced renal blood
flow [13], release of certain hormones such as antidiuretic hor-
mone (ADH), plasma rennin activity, and serum aldosterone
may diminish urine output [14].
Hydroxyethyl starch (HES) 130/0.4 is indicated for the
treatment and prophylaxis of hypovolemia. As its molecule
is smaller than the other available hydroxyethyl starch prod-
ucts, it is associated with less plasma accumulation and can
be safely used in patients with renal impairment. Previous
studies have demonstrated that it has comparable effects on
volume expansion and hemodynamics as other available
HES products. It is also associated with fewer effects on coag-
ulation and may be an acceptable alternative to albumin for
volume expansion in situations in which other starches are
contraindicated secondary to risk of coagulopathy [15].
In a trial to overcome the adverse effects of pneumoperi-
toneum during laparoscopic GBP on renal function we inves-
tigated the effects of third generation HES 130/0.4 (6%) on
renal function and blood loss during laparoscopic GBP. We
revealed that, infusion of HES 130/0.4 has role in the preven-
tion of oliguria and provide renal protection without effect on
hemostasis and intraoperative or postoperative blood loss.
This could be explained by the state of hypervolemia which
occurred after infusion of HES 130/0.4 and remained in the
circulation longer than crystalloid which led to stable hemody-
namics during surgery and no episodes of hypotension with
near normal mean arterial blood pressure which provides ade-
quate renal perfusion and adequate urine output intraopera-
tively and normal renal function postoperatively so we can
conclude that the state of hypervolemic hemodilution with
HES 130/0.4 after induction of anesthesia can overcome the
adverse effect of prolonged pneumoperitoneum on renal func-
tion and provide renal protection during GBP. Also, the HES
130/0.4 has rapid metabolism and renal excretion and is more
superior as regards renal safety when compared to older type
of HES.
Demyttenaere et al. [16] concluded that both renal function
and renal blood flow (RBF) are decreased during pneumoperi-
toneum. The magnitude of the decrease is dependent on fac-
tors such as preoperative renal function, level of hydration,
level of pneumoperitoneum, patient positioning, and duration
of pneumoperitoneum.
In agreement with the present study, Jover et al. [17] con-
cluded that, prehyderation with HES can be an effective
method in renal protection during laparoscopic cholecystec-
tomy. Also Osthaus et al. [18] revealed that the negative effects
of prolonged pneumoperitoneum (PP) on hemodynamics and
acid-base balance can be obviated by a liberal plasma volume
stabilization regimen with colloids. Also, an experimental
study by London et al. [19] concluded that Intravascular vol-
ume expansion alleviates the effects of CO2 pneumoperi-
toneum on renal hemodynamics in a porcine model.
Hypertonic saline (7.5% NaCl) solution may maximize renal
blood flow in prolonged pneumoperitoneum, but it does not
completely prevent renal dysfunction in this setting. This study
suggests that routine intraoperative volume expansion is
important during laparoscopic live donor nephrectomy.Regarding, intraoperative and postoperative blood loss, the
present study found that the infusion of new HES has no
effects on homeostasis and no major blood loss has occurred.
This is in agreement with Jungheinrich et al. [20] who showed
that the perioperative infusion of hydroxyethyl starch 130/0.4
(6%) in orthopedic surgery resulted in a normal coagulation
profile 5 h post surgery, in contrast to hydroxyethyl starch
200/0.5. This could be explained by rapid normalization of
decreased von Willebrand factor and factor VIII due to the
faster elimination of hydroxyethyl starch 130/0.4 compared
with hydroxyethyl starch 200/0.5 [21–23].
The increased therapeutic safety index of the
third-generation hydroxyethyl starch 130/0.4 compared with
hydroxyethyl starch 200/0.5 was acknowledged by European
regulatory authorities by increasing the maximum daily dose
to 50 mL/kg bodyweight, which is the highest dose for any
hydroxyethyl starch type approved so far [24].
In contrast to the present study, Chan et al. [25] concluded
that the use of HES is unnecessary and should be avoided in
most elective bariatric surgery cases as it leads to coagulation
abnormalities and increases the risk of postoperative bleeding.
4. Conclusion
Infusion of HES 130/0.4 has role in prevention of oliguria and
provides renal protection without effect on hemostasis and
intraoperative or postoperative blood loss.Conﬂict of Interest Disclosure
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